MarginsXMarginsX
Home › Markets › Health Care › VRCA

Verrica Pharmaceuticals Inc. (VRCA)

VRCA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.20
-10.11% on the day
Market cap
$55.0M
Micro cap
Revenue · 2025
$35.6M
+370.2% on 2024
Net income · 2025
-$17.9M
-50.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1660334/000166033426000008/0001660334-26-000008-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerVRCA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2018
SEC CIK0001660334
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$35.6M
Net income-$17.9M
Operating income-$12.2M
Net margin-50.3%
Operating margin-34.2%
Revenue growth+370.2%
Cash$30.1M
Total assets$47.1M
P/E (computed)Net income was not positive
P/S (computed)1.5×

Warning signs

Cash runway
10.1 months
$11.2M cash at June 30, 2026
Share count, 1 year
+81.0%
2025-11-07 to 2026-11-05 · +308.4% over 3 years
Going-concern doubt
Yes
10-Q filed November 13, 2026
Insider net buying, 12 months
$6.5M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Based on the current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding, the Company has concluded that substantial doubt exists regarding its ability to continue as a going concern within one year after the date these consolidated financial statements are issued."
10-Q 2026-11-13
Cash and burn$11.2M cash; operating cash flow -$3.3M a quarter.Report 2026-06-30
Shares outstanding17,178,786 (2026-11-05); 9,490,035 a year earlier; 42,064,553 three years earlier. 3y figure adjusted for split (1-for-10 overall).Cover page 2026-11-05
Reverse splits, 3 years1; latest 1-for-10 on 2025-07-25Source 2025-07-25
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2025-12-15
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Philadelphia, Pennsylvania, United StatesPCAOB Form AP 2026-04-01
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $6.5M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$5.9M-$13.2M-$9.3M$11.2MNo debt tags$30.3M10-Q 2026-08-06
Q1 2026
2026-03-31
$5.0M-$9.7M-$9.2M$20.6MNo debt tags$37.2M10-Q 2026-05-12
Q4 2025
2025-12-31
$5.1M-$8.1M-$4.6M$30.1M$0$35.6M10-K 2026-03-11
Q3 2025
2025-09-30
$14.3M-$274K$9.7M$21.1M$21.6M$30.8M10-Q 2025-11-14
Q2 2025
2025-06-30
$12.7M$204K-$10.0M$15.4M$24.6M$14.7M10-Q 2026-08-06
Q1 2025
2025-03-31
$3.4M-$9.7M-$12.7M$29.6M$27.8M$7.2M10-Q 2026-05-12
Q4 2024
2024-12-31
$344K-$16.2M-$16.1M$46.3M$31.0M$7.6M10-K 2026-03-11
Q3 2024
2024-09-30
-$1.8M-$22.9M-$8.6M$23.0M$43.3M$9.2M10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32025-12-23
Latest annual report10-K2026-03-11
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-04-20

Source: SEC EDGAR submissions feed, 538 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+11.6%
1 month-0.6%
3 months-26.7%
Year to date-57.2%
1 year-8.0%
From 52-week high-60.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
SPROSpero Therapeutics Inc.$0.9464-5.35%$55.1M
CINGCingulate Inc.$3.75-12.79%$54.5M
INCRIntercure Ltd.$3.63-4.22%$54.5M
AZRAzora Therapeutics Inc.$3.81-6.85%$54.4M
XLOXilio Therapeutics Inc.$7.70-3.08%$54.4M
HRTXHeron Therapeutics Inc.$0.2843-8.44%$54.1M
TNXPTonix Pharmaceuticals Holding Corp.$2.88-4.32%$56.0M
XBITXBiotech Inc.$1.85-5.37%$56.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier